Informed Prostate Cancer Patient Support

Summary The androgen receptor targeted agents (ARTA) typically used in prostate cancer treatment include: 1. Abiraterone 2. Enzalutamide 3. Apalutamide 4. Darolutamide 5. Orteronel The article mentions that these were the ARTA agents used in the studies included in the systematic review and meta-analysis conducted by Ong et al. It's worth noting that these agents are often used in combination with androgen deprivation therapy (ADT) for the treatment of metastatic prostate cancer. The article also points out that in many countries, including the author's, the use of an ARTA in combination with either an LHRH (luteinizing hormone-releasing hormone) agonist or antagonist has received Medicare funding for patients with metastatic prostate cancer. This is due to the observed benefits in long-term prostate cancer-specific survival and freedom from progressive disease. Each of these agents may have different risk profiles and efficacy, but the article suggests that more research is ne